Immune checkpoint inhibitors like pembrolizumab and atezolizumab work by unleashing anti-tumor T-cell responses and have gained approval in TNBC—pembrolizumab for PD-L1–positive metastatic TNBC and for high-risk early-stage disease [22,23], and atezolizumab (with nab-paclitaxel) as the first checkpoint inhibitor approved for advanced TNBC with PD-L1 expression [24]. The gene discussed is CD274; the disease is neoplasm.